التفاصيل البيبلوغرافية
| العنوان: |
Effect of trimetazidine on left ventricular functions and cardiac biomarkers in diabetic patients with left ventricular diastolic dysfunction: a randomized controlled trial. |
| المؤلفون: |
Serag, Heba1 (AUTHOR) heba.ibrahim@pharma.asu.edu.eg, Wakeel, Lamia El1 (AUTHOR), William, Viola2 (AUTHOR), Abdelsalam, Mona3 (AUTHOR), Abdelsalam, Ahmed2 (AUTHOR), Sayed, Rana1 (AUTHOR) |
| المصدر: |
Scientific Reports. 1/16/2025, Vol. 15 Issue 1, p1-14. 14p. |
| مصطلحات موضوعية: |
*LEFT ventricular dysfunction, *TRANSFORMING growth factors-beta, *GLOBAL longitudinal strain, *TUMOR necrosis factors, *DIABETIC cardiomyopathy, *BRAIN natriuretic factor |
| مستخلص: |
We investigated the impact of trimetazidine treatment on left ventricular (LV) functions and cardiac biomarkers in diabetic patients with diastolic dysfunction as an early stage of diabetic cardiomyopathy. Sixty-three patients were randomly assigned to receive either trimetazidine or a placebo for 3 months. At baseline and after 3-months of treatment, measurements of serum levels of glycemic control parameters, lipid profile, tumor necrosis factor alpha, transforming growth factor beta 1, n-terminal pro brain natriuretic peptide and assessment of modified Medical Research Council (mMRC) dyspnea score, echocardiographic indices of LV functions and LV global longitudinal strain (GLS) were performed. After 3-months, trimetazidine group exhibited a significant reduction in left atrial volume index by 6.99% versus an increase by 0.66% in placebo group, p = 0.034. Moreover, average e' increased by a significantly higher percentage in trimetazidine versus placebo group (8.46 ± 18.64 vs. -2.49 ± 14.52, respectively. p = 0.015). Trimetazidine treatment resulted in a significant increase in LVGLS by 6.66% versus LVGLS reduction by 2.79% in placebo group (p = 0.004). Trimetazidine group had a significantly lower median mMRC dyspnea score compared to placebo (0 vs. 1, respectively, p = 0.015) and a significantly lower low-density lipoprotein (LDL-C) (103.43 ± 28.31 vs. 125.34 ± 45.27, respectively, p = 0.032). There was no significant difference between both groups in levels of other biomarkers. Three-months treatment with trimetazidine improved diastolic function parameters, LVGLS, dyspnea severity and LDL-C levels in diabetic patients with diastolic dysfunction. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder